TY 12533

Drug Profile

TY 12533

Latest Information Update: 31 Oct 2003

Price : $50

At a glance

  • Originator Toa Eiyo
  • Class Anti-ischaemics
  • Mechanism of Action Sodium hydrogen antiporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Arrhythmias; Reperfusion injury

Most Recent Events

  • 31 Oct 2003 Discontinued - Preclinical for Reperfusion injury in Japan (unspecified route)
  • 31 Oct 2003 Discontinued - Preclinical for Arrhythmias in Japan (unspecified route)
  • 12 Sep 2001 A study has been added to the Ischaemic Heart Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top